$RGBP NEW OUT
SAN DIEGO, April 28, 2016 /PRNewswire/ --
Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) has entered into a non-exclusive license agreement with Pan Am Cancer Treatment Center in Tijuana, Mexico to test HemaXellerate in a first-in-human proof of concept study. Up to 10 patients with chemotherapy-induced aplastic anemia will be treated with HemaXellerate, and outcomes will be measured at one, three and six months. This study was initiated by Dr. Julio Selva Pallares, Professor of Clinical Hematology at the Autonomous University of Baja California and Director of its hematology transfusion unit.
"We were delighted that Dr. Pallares initiated this trial and that Regen could support him. We hope that HemaXellerate will benefit these patients," said Dr. David Koos, CEO of Regen BioPharma. "As an investigator-initiated trial, the license does not have a financial component. The first-in-human study, however, is very valuable to our research."
HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. The FDA recently cleared Regen to perform phase I clinical trials in the U.S. using HemaXellerate for patients battling aplastic anemia.
"It is very exciting to have our first clinical stage product licensed for a proof of concept study so quickly. Our HemaXellerate program is advancing, and we anticipate the other autologous cell therapies for which we are seeking FDA IND clearance, dCellVax and tCellVax, to follow a similar path," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
The license granted to Pan Am Cancer Treatment Center grants only the right to test HemaXellerate in a human proof of concept study. The license granted does not permit Pan Am Cancer Treatment Center to market the therapy or provide the therapy to any party other than in connection with their study.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
http://www.regenbiopharma.com and http://www.regenbiopharmainc.com
Twitter: Regen BioPharma News: https://twitter.com/RegenBioPharm
SAN DIEGO, April 28, 2016 /PRNewswire/ --
Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) has entered into a non-exclusive license agreement with Pan Am Cancer Treatment Center in Tijuana, Mexico to test HemaXellerate in a first-in-human proof of concept study. Up to 10 patients with chemotherapy-induced aplastic anemia will be treated with HemaXellerate, and outcomes will be measured at one, three and six months. This study was initiated by Dr. Julio Selva Pallares, Professor of Clinical Hematology at the Autonomous University of Baja California and Director of its hematology transfusion unit.
"We were delighted that Dr. Pallares initiated this trial and that Regen could support him. We hope that HemaXellerate will benefit these patients," said Dr. David Koos, CEO of Regen BioPharma. "As an investigator-initiated trial, the license does not have a financial component. The first-in-human study, however, is very valuable to our research."
HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. The FDA recently cleared Regen to perform phase I clinical trials in the U.S. using HemaXellerate for patients battling aplastic anemia.
"It is very exciting to have our first clinical stage product licensed for a proof of concept study so quickly. Our HemaXellerate program is advancing, and we anticipate the other autologous cell therapies for which we are seeking FDA IND clearance, dCellVax and tCellVax, to follow a similar path," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
The license granted to Pan Am Cancer Treatment Center grants only the right to test HemaXellerate in a human proof of concept study. The license granted does not permit Pan Am Cancer Treatment Center to market the therapy or provide the therapy to any party other than in connection with their study.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
http://www.regenbiopharma.com and http://www.regenbiopharmainc.com
Twitter: Regen BioPharma News: https://twitter.com/RegenBioPharm
All of my posts are honest, opinion based statements from due diligence performed by myself.
